ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

ClinicalTrials.gov ID: NCT00324155

Public ClinicalTrials.gov record NCT00324155. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

Study identification

NCT ID
NCT00324155
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
681 participants

Conditions and interventions

Conditions

Interventions

  • Dacarbazine Drug
  • Ipilimumab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2006
Primary completion
Dec 31, 2010
Completion
Sep 30, 2013
Last update posted
Nov 2, 2014

2006 – 2013

United States locations

U.S. sites
32
U.S. states
19
U.S. cities
31
Facility City State ZIP Site status
Pacific Cancer Medical Center Anaheim California 92801
Wilshire Oncology Medical Group Inc La Verne California 91750
The Angeles Clinic And Research Institute Los Angeles California 90025
Comprehensive Cancer Center Palm Springs California 92262
Sharp Clinical Oncology Research San Diego California 92123
Saint Francis Hospital And Medical Center Hartford Connecticut 06105
Hematology Oncology, P.C. Stamford Connecticut 06902-3628
Cancer Specialists Of North Florida Beaches Jacksonville Florida 32256
Orlando Health, Inc. M.D. Anderson Cancer Center Orlando Orlando Florida 32806
Hematology Oncology Associates Of The Treasure Coast Port Saint Lucie Florida 34952
University Of Chicago Chicago Illinois 60637
Mid-Illinois Hematology/Oncology Associates, Ltd. Normal Illinois 61761
Oncology Specialists, Sc Park Ridge Illinois 60068
Central Indiana Cancer Centers Fishers Indiana 46037
Indiana University Cancer Center Indianapolis Indiana 46202
Hutchinson Clinic, Pa Hutchinson Kansas 67502
Kentucky Cancer Clinic Hazard Kentucky 41701
Greater Baltimore Medical Center Baltimore Maryland 21204
Sinai Hospital Of Baltimore Baltimore Maryland 21215
Dana Farber Cancer Institute Boston Massachusetts 02115
Ellis Fischel Cancer Center Columbia Missouri 65203
St Joseph Oncology Inc Saint Joseph Missouri 64507
University Of New Mexico Cancer Center Albuquerque New Mexico 87106
Memorial Sloan Kettering Cancer Center New York New York 10065
Blumenthal Cancer Center Charlotte North Carolina 28204
Providence Portland Medical Center Portland Oregon 97213
St. Luke'S Hospital & Health Network Bethlehem Pennsylvania 18015
Lowcountry Hematology & Oncology, Pa Mt. Pleasant South Carolina 29464
Thompson Cancer Survival Center Knoxville Tennessee 37916
Vanderbilt-Ingram Cancer Ctr Nashville Tennessee 37232
Joe Arrington Cancer Research And Treatment Center Lubbock Texas 79410
Virginia Cancer Institute Richmond Virginia 23226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 95 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00324155, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 2, 2014 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00324155 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →